U.S. markets close in 40 minutes

NuCana plc (NCNA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
0.7998+0.0047 (+0.59%)
As of 03:12PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Fast Stochastic

Fast Stochastic

Previous Close0.7951
Bid0.7702 x 1100
Ask0.7999 x 1300
Day's Range0.7702 - 0.8405
52 Week Range0.5170 - 3.3200
Avg. Volume84,909
Market Cap41.746M
Beta (5Y Monthly)1.28
PE Ratio (TTM)N/A
EPS (TTM)-0.9200
Earnings DateNov 16, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.75
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for NCNA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • NuCana plc
    November Rally in a Reshaped MarketThe Portfolio Selector features the Argus Focus List, a group of 30 "best idea" stocks generated and regularly updated by Argus' analysts and investment policy committee. It also includes the director of research’s monthly investment strategy column, stock recommendations and sector picks, economic forecasts, and an asset allocation model. This month, the Focus List additions are Corteva Inc (CTVA); Dell Technologies Inc (DELL); Exxon Mobil Corp. (XOM); Thermo Fisher Scientific Inc. (TMO) and the Focus List deletions are Linde Plc (LIN); Lilly(Eli) & Co (LLY); ASML Holding NV (ASML); EOG Resources, Inc. (EOG).
    Fair Value
    Economic Moat
    3 days agoArgus Research
View more
  • Zacks

    NuCana PLC Sponsored ADR (NCNA) Upgraded to Buy: What Does It Mean for the Stock?

    NuCana PLC Sponsored ADR (NCNA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

  • GlobeNewswire

    NuCana Reports Third Quarter 2022 Financial Results and Provides Business Update

    Multiple Data Readouts on Track for the Remainder of 2022 and the First Half of 2023 Well Capitalized with Anticipated Cash Runway into 2025 EDINBURGH, United Kingdom, Nov. 16, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial results for the third quarter ended September 30, 2022 and provided an update on its broad clinical program with its transformative ProTide therapeutics. As of September 30, 2022, NuCana had cash and cash equivalents of £50.8 million compared to £46.5

  • GlobeNewswire

    NuCana to Present at the Jefferies London Healthcare Conference

    EDINBURGH, United Kingdom, Nov. 08, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-one meetings at the Jefferies London Healthcare Conference. Event: Jefferies London Healthcare ConferenceDates: Wednesday, November 16, 2022Time: 2:40 PM GMTLocation: London, UK The presentation will be webcast live and available for replay under “Events & Presentations” in the Inve